PUMA BIOTECH Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PUMA BIOTECH, and what generic alternatives to PUMA BIOTECH drugs are available?
PUMA BIOTECH has one approved drug.
There are ten US patents protecting PUMA BIOTECH drugs.
There are one hundred and seventy-one patent family members on PUMA BIOTECH drugs in thirty-five countries and eight supplementary protection certificates in eight countries.
Summary for PUMA BIOTECH
| International Patents: | 171 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for PUMA BIOTECH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 8,669,273 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 8,790,708 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,399,865 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 9,265,784 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 9,139,558 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,982,043 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PUMA BIOTECH
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | 6,288,082 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PUMA BIOTECH Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5681108 | ⤷ Subscribe |
| China | 105999264 | ⤷ Subscribe |
| Canada | 2702930 | ⤷ Subscribe |
| Japan | 2017043640 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2009052264 | ⤷ Subscribe |
| China | 113209121 | ⤷ Subscribe |
| Singapore | 10202102855R | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for PUMA BIOTECH Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3000467 | CA 2023 00021 | Denmark | ⤷ Subscribe | PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180904 |
| 3000467 | 2390021-0 | Sweden | ⤷ Subscribe | PRODUCT NAME: NERATINIB; REG. NO/DATE: EU/1/18/1311 20180904 |
| 3000467 | 301237 | Netherlands | ⤷ Subscribe | PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180904 |
| 3000467 | 2023C/527 | Belgium | ⤷ Subscribe | PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904 |
| 3000467 | 26/2023 | Austria | ⤷ Subscribe | PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 (MITTEILUNG) 20180904 |
| 3000467 | LUC00310 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: NERATINIB; AUTHORISATION NUMBER AND DATE: EU/1/18/1311 20180904 |
| 3000467 | 122023000045 | Germany | ⤷ Subscribe | PRODUCT NAME: NERATINIB; REGISTRATION NO/DATE: EU/1/18/1311 20180831 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
